The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine; Rain Therapeutics
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - Apexigen; Array BioPharma; Astex Pharmaceuticals; Bionaut Labs; Concarlo; Ellipses Pharma; Epizyme; Gencirq; January Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Sellas Life Sciences; Shanghai Pharma
Research Funding - Adaptimmune (Inst); Astex Pharmaceuticals; Astex Pharmaceuticals (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Oxford BioTherapeutics (Inst); SpringWorks Therapeutics (Inst); TopAlliance BioSciences Inc (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Epizyme; Epizyme; Epizyme
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Aadi; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Astex Pharmaceuticals; Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Andrew J. Wagner
Honoraria - Deciphera
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Lilly; Mundipharma
Research Funding - AADi (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
Gregory Michael Cote
Consulting or Advisory Role - C4 Therapeutics; Foghorn Therapeutics; Ikena Oncology
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Repare Therapeutics (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Robert G Maki
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Lilly; Deciphera; Ipsen; Karyopharm Therapeutics; PEEL Therapeutics; TRACON Pharma; UpToDate
Speakers' Bureau - PER
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi (Inst); Exelixis (Inst); InhibRx (Inst); PEEL Therapeutics (Inst); Presage Biosciences (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Regeneron (Inst); SARC: Sarcoma Alliance for Research though Collaboration (Inst); SpringWorks Therapeutics (Inst); SynOx (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - SpringWorks Therapeutics; TRACON Pharma
 
Hanna Kosela-Paterczyk
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Dale Randall Shepard
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Celgene; Genentech/Roche
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); GITR (Inst); Harpoon therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Nektar (Inst); PsiOxus Therapeutics (Inst); Shanghai Miracogen Inc. (Inst); VBL Therapeutics (Inst)
 
Naisargee Shah
Employment - Puma Biotechnology; Rain Therapeutics
Stock and Other Ownership Interests - Puma Biotechnology; Rain Therapeutics
 
Richard Bryce
Employment - Puma Biotechnology; Rain Therapeutics
Leadership - Puma Biotechnology; Rain Therapeutics
Stock and Other Ownership Interests - Puma Biotechnology; Rain Therapeutics
Travel, Accommodations, Expenses - Puma Biotechnology; Rain Therapeutics
 
Robert Charles Doebele
Employment - Rain Therapeutics
Leadership - Rain Therapeutics
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; GreenPeptide; Guardant Health; Rain Therapeutics; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Licensing fees for patent from Rain Therapeutics; Licensing fees from Takeda for Biologic Materials; Licensing fees from ThermoFisher for Biologic Materials
 
Shreyaskumar Patel
Consulting or Advisory Role - Adaptimmune; Bayer; Daiichi Sankyo; Deciphera; GlaxoSmithKline
Research Funding - Blueprint Medicines (Inst); HUTCHMED (Inst); Rain Therapeutics (Inst)